<DOC>
	<DOCNO>NCT01306604</DOCNO>
	<brief_summary>Niemann Pick Syndrome Type C lysosomal storage disorder , cause pathological overload cell unesterified cholesterol result impair lipid transport cell , still problem difficulty simple reliable analysis primary diagnosis also follow-up disease . Therefore primary aim project call `` BioNPC '' development new plasma biomarker early sensitive diagnosis disease . The secondary aim test clinical robustness , specificity long-term stability biomarker . Within scope study investigator would like collect next 12 month 80 patient 's plasma parallel simple documentation clinical data .</brief_summary>
	<brief_title>Biomarker Niemann Pick Type C Disease</brief_title>
	<detailed_description>Niemann-Pick disease type C ( NPC ) lipid storage disease present infant , child , adult . Neonates present ascites severe liver disease infiltration liver and/or respiratory failure infiltration lung . Other infant , without liver pulmonary disease , hypotonia developmental delay . The classic presentation occur mid-to-late childhood insidious onset ataxia , vertical supranuclear gaze palsy ( VSGP ) , dementia . Dystonia seizures common . Dysarthria dysphagia eventually become disabling , make oral feeding impossible ; death usually occur late second third decade aspiration pneumonia . Adults likely present dementia psychiatric symptom . The diagnosis NPC confirm biochemical testing demonstrates impair cholesterol esterification positive fillipin stain cultured fibroblast . Biochemical test carrier status unreliable . Most individual NPC NPC1 , cause mutation NPC1 gene ; few 20 individual diagnose NPC2 , cause mutation NPC2 gene . Molecular genetic test NPC1 gene detect disease-causing mutation approximately 94 % individual NPC . Such test available clinically . NPC inherit autosomal recessive manner . Each sib affect individual 25 % chance affect , 50 % chance asymptomatic carrier , 25 % chance unaffected carrier . The phenotype ( i.e. , age onset severity symptom ) usually run true family . Carrier test at-risk relative prenatal test pregnancy increase risk possible two disease-causing mutation identify family . Since accept easily accessible lab test , Fillipin stain skin fibroblast , invasive rather low sensitivity specificity genetic sequence tome-consuming expensive urgent need improvement diagnostic biomarkers . New method , like mass-spectometry give good chance characterize blood ( plasma ) affect patent specific metabolic alteration allow diagnose future disease earlier , high sensitivity specificity . The development new biochemical marker plasma affected patient goal study .</detailed_description>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Niemann-Pick Diseases</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type A</mesh_term>
	<mesh_term>Niemann-Pick Disease , Type C</mesh_term>
	<criteria>Written inform consent obtain patient parent study related procedure Patients first day life The patient diagnosis Niemann Pick Type C syndrome NPC1/NPC2 profound suspicion Niemann Pick Type C syndrome NPC1/NPC2 disease Highgrade suspicion present , one criterion valid : Positive family anamnesis NPC1/NPC2 Splenomegaly without identifiable cause Hepatomegaly without identifiable cause Neurological symptom without identifiable cause Psychiatric symptom without identifiable cause No write informed consent obtain patient parent study related procedure No diagnosis NPC1/NPC2 valid criterion highgrade suspicion NPC1/ NPC2</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Genetic Diseases</keyword>
	<keyword>Lipidoses</keyword>
	<keyword>Lipid Metabolism</keyword>
	<keyword>Lysosomal Storage Diseases</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Lipid Metabolism Disorders</keyword>
</DOC>